Literature DB >> 12500027

Importance of creatine kinase activity for functional recovery of myocardium after ischemia-reperfusion challenge.

Patricia Rodriguez1, Martin Avellanal, Antonio Felizola, Santos Barrigon.   

Abstract

To define the relation between the phosphoryl transfer via creatine kinase and the ability to recover from an ischemia-reperfusion challenge, the authors chemically inhibited creatine kinase activity with iodoacetamide (IAm) and then measured myocardial recovery after 2, 10, or 30 min of global ischemia followed by 30 min of reperfusion in the isolated, arterially perfused interventricular septa of the rabbit heart. During normoxia, IAm (0.5 M perfused for 15 min) did not by itself modify developed tension, maximal rate of tension development, or resting tension. In ischemia, IAm pretreatment increased the rate of developed tension loss and highly diminished developed tension recovery after reperfusion for all the ischemia periods tested. Moreover, IAm significantly enhanced the maximal increase in the resting tension induced by 10 or 30 min of ischemia plus reperfusion. Lactate dehydrogenase activity in reperfusion was also significantly increased over untreated septa. On the basis of the present results, the authors suggest that the aggravating effects exhibited by IAm on the ischemic myocardium are compatible with its creatine kinase inhibition properties and that creatine kinase activity is essential for full recovery from an ischemia-reperfusion challenge.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12500027     DOI: 10.1097/00005344-200301000-00013

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  1 in total

1.  Creatine kinase overexpression improves ATP kinetics and contractile function in postischemic myocardium.

Authors:  Ashwin Akki; Jason Su; Toshiyuki Yano; Ashish Gupta; Yibin Wang; Michelle K Leppo; Vadappuram P Chacko; Charles Steenbergen; Robert G Weiss
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-10       Impact factor: 4.733

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.